RxDoctor Payments Data

Daniel Apple, MD

Ophthalmology · Detroit, MINPI 1649565045

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,940 of the $9,891 with a category attached, or 60.1%. Genentech USA, Inc. accounts for 78.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $7,660 and has fallen 93.4% since, to $502 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,891in general payments, 2019–2025

Across 118 payments — averaging $83.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$8K
  • Regeneron Healthcare Solutions, Inc.$465
  • AbbVie$331
  • Bausch & Lomb Americas Inc.$257
  • Apellis Pharmaceuticals, Inc.$216
  • Oculus Surgical Inc.$171
  • plus $651 from 6 others
$14,205in research payments, 2019–2025

Across 15 payments — averaging $947.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$14K

What the payments were for

  • Consulting fees$5,94060%
  • Travel & lodging$1,10911%
  • Food & beverage$2,74228%
  • Education$1001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,891 in reported general payments places this provider in the 90th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$2,353,079
Medicare patients
945
Services billed
30,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate134$6,006
ProlensaBromfenac Sodium11$4,495
Ketorolac Tromethamine75$1,253
Ofloxacin57$554
Atropine Sulfate12$476
Brimonidine Tartrate41$323
ErythromycinErythromycin Base12$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$143$4,49511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →